

Zeniquin®

Common Drug Name - Marbofloxacin

How Supplied by SmartPak –Zeniquin is available in 25mg and 50mg strengths, in 100-count bottle sizes.

Category – Zeniquin is a synthetic broadspectum antibacterial agent from the fluoroquinolone class of chemotherapeutic agents.

Caution - Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in foodproducing animals.

Indications (Uses) – Zeniquin is for the treatment of infections in dogs and cats associated with bacteria susceptible to Marbofloxacin.

Dosage and Administration – The recommended dosage for oral administration to dogs and cats is 1.25mg Marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5mg/lb. For the treatment of skin and soft tissue infections, Zeniquin should be given for 2 – 3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Zeniquin should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Contraindications – Marbofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. Marbofloxacin is contraindicated in immature dogs during the rapid growth phase (small and medium

breeds up to 8 months of age, large breeds up to 12 months of age and giant breeds up to 18 months of age). Marbofloxacin is contraindicated in cats under 12 months of age. Marbofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones.

Human Warnings – Not for human use. Keep out of reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposure. Individuals with a history of hypersensitivity to fluoroquinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quionolones. If excessive accidental exposure occurs, avoid direct sunlight.

Drug Interactions – Compounds (e.g. Sucralfate, antacids and mineral supplements) containing divalent and trivalent cations (e.g. iron, aluminum, calcium, magnesium and zinc) can interfere with the absorption of quionolones which may result in a decrease in product bioavailability. Therefore, the concomitant oral administration of quionolones with foods, supplements or other preparations containing these compounds should be avoided.

Precautions – Quinolones should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolones have been shown to

produce erosions of cartilage of weightbearing joints and other signs of arthropathy in immature animals of various species. The use of fluroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. The safety of marbofloxacin in animals used for breeding purposes, pregnant, or lactating has not been demonstrated.

Adverse Reactions (Side Effects) – The following clinical signs were reported during the course of clinical field studies in dogs receiving marbofloxacin at doses up to 2.5mg/lb daily: decreased or loss of appetite (5.4%), decreased activity (4.4%) and vomiting (2.9%). The following clinical signs were reported during clinical field studies in cats receiving 1.25mg/lb daily: diarrhea (2.1%) and soft stool (1.4%).

Storage Conditions: Store below 86F.

Distributed by:

Pfizer Animal Health Exton, PA 19341

Rev 1/08

SmartPakTM
40 Grissom Road, Suite 500
Plymouth, MA 02360
Phone: 1-800-431-4194
Fax: 1-800-431-4179

www.SmartPak.com